Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/12079
|
| Title: | Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with |
| Authors: | Pelzer, U;Blanc, JF;Melisi, D;Cubillo, A;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Siveke, JT;Wan, Y;Solem, CT;Botteman, M;Yang, Y;de Jong, F;Hubner, R |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Background: nal-IRI is a nanoliposomal formulation of irinotecan. In the primary analysis of the pivotal NAPOLI-1 Phase-3 trial, nal-IRI+5-FU/LV significantly improved median overall survival (OS, primary endpoint; 6.1 vs 4.2 months, HR = 0.67, P = 0.012) and progression-free survival (PFS; 3.1 vs 1.5 months, HR = 0.56, P = 0.0001) vs 5-FU/LV alone in mPAC pts previously treated with gemcitabine-based therapy. This analysis evaluates between-treatment differences in quality-adjusted survival using a Q-TWiST approach. Methods: Total survival in NAPOLI-1 intent-to-treat cohort over 12 months was partitioned into time with adverse event grade ≥ 3 toxicity (TOX), time in relapse after disease progression (REL), and time without symptoms or adverse event grade ≥ 3 toxicity (TWiST). Mean Q-TWiST was calculated by multiplying time spent in each health state by its respective utility. In the base-case, the utility for TOX (uTOX), REL (uREL) and TWIST (uTWiST) were set to 0.5, 0.5 and 1.0. Nonparametric bootstrapped 95% CIs were derived. The relative Q-TWiST gain of nal-IRI+5-FU/LV vs mean OS for 5-FU/LV was calculated. Threshold analyses varied uTOX and uTWiST between 0.0 and 1.0. Scenario analysis was conducted using per-protocol (PP) population. Results: Nal-IRI+5-FU/LV (n = 117) vs 5-FU/LV (n = 119) pts had significantly more time in TWiST (mean 3.4 vs 2.4 months) and TOX (1.0 vs 0.3 month) but similar time in REL (2.5 vs 2.7 months). In the base-case, nal-IRI+5-FU/LV pts had a 1.3 months (95% CI: 0.4–2.1; 5.1 vs 3.9) greater Q-TWiST (range threshold analyses: 0.9–1.6 months), with a relative Q-TWiST gain of 24% (range threshold analyses: 17%-31%). In the PP population, Q-TWiST was also significantly superior in MM-398+5-FU/LV pts (Q-TWiST gain = 1.8 months; 95% CI: 0.7–3.0). Conclusions: Within NAPOLI-1, combination of nal-IRI+5-FU/LV resulted in statistically significant and clinically important gains in quality-adjusted survival vs 5-FU/LV alone, confirming the clinical outcome benefit of nal-IRI+5-FU/LV in mPAC. |
| Date: | 2016-05 |
| Relation: | Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15732. |
| Link to: | http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e15732 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000404665407050 |
| Appears in Collections: | [陳立宗] 會議論文/會議摘要
|
Files in This Item:
There are no files associated with this item.
|
All items in NHRI are protected by copyright, with all rights reserved.
|
